EPS for BCE Inc. (BCE) Expected At $0.81; Ampio Pharmaceuticals (AMPE) Sentiment Is 2.3

April 17, 2018 - By Maria Brooks

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Logo

Ampio Pharmaceuticals Inc (AMPE) investors sentiment increased to 2.3 in 2017 Q4. It’s up 1.75, from 0.55 in 2017Q3. The ratio has increased, as 23 investment professionals opened new or increased positions, while 10 decreased and sold stakes in Ampio Pharmaceuticals Inc. The investment professionals in our database reported: 8.34 million shares, up from 6.66 million shares in 2017Q3. Also, the number of investment professionals holding Ampio Pharmaceuticals Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 2 Reduced: 8 Increased: 11 New Position: 12.

Analysts expect BCE Inc. (TSE:BCE) to report $0.81 EPS on May, 3 before the open.They anticipate $0.06 EPS change or 6.90% from last quarter’s $0.87 EPS. T_BCE’s profit would be $729.85 million giving it 16.67 P/E if the $0.81 EPS is correct. After having $0.76 EPS previously, BCE Inc.’s analysts see 6.58% EPS growth. The stock decreased 0.30% or $0.16 during the last trading session, reaching $54.02. About 343,703 shares traded. BCE Inc. (TSE:BCE) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

BCE Inc., a telecommunications and media company, provides wireless, wireline, Internet, and television services to residential, business, and wholesale clients in Canada. The company has market cap of $48.68 billion. The firm operates through three divisions: Bell Wireless, Bell Wireline, and Bell Media. It has a 17.37 P/E ratio. The Bell Wireless segment offers integrated digital wireless voice and data communications services and products.

Among 9 analysts covering BCE Inc. (TSE:BCE), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. BCE Inc. had 34 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Thursday, December 17. Barclays Capital maintained the stock with “Outperform” rating in Friday, August 28 report. The rating was upgraded by TD Securities on Wednesday, September 2 to “Buy”. The stock has “Neutral” rating by Credit Suisse on Monday, January 4. The company was downgraded on Friday, July 24 by Desjardins Securities. Scotia Capital maintained it with “Outperform” rating and $59 target in Friday, August 7 report. The company was maintained on Friday, April 29 by RBC Capital Markets. The firm has “Sector Perform” rating given on Friday, November 6 by National Bank Canada. The firm earned “Outperform” rating on Monday, August 31 by BMO Capital Markets. The rating was maintained by Barclays Capital on Monday, August 3 with “Overweight”.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company has market cap of $247.75 million. The firm is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. It currently has negative earnings. The Company’s product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema.

Knoll Capital Management Lp holds 9.31% of its portfolio in Ampio Pharmaceuticals, Inc. for 2.60 million shares. Cypress Capital Management Llc (Wy) owns 108,400 shares or 0.5% of their US portfolio. Moreover, Noven Financial Group Inc. has 0.37% invested in the company for 158,059 shares. The Colorado-based Ghp Investment Advisors Inc. has invested 0.06% in the stock. Brighton Jones Llc, a Washington-based fund reported 30,555 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Maria Brooks

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: